Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026)

Palisade Bio (PALI) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$10.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 382.02% year-over-year to -$10.7 million in Q1 2026; TTM through Mar 2026 was -$26.4 million, a 100.14% decrease from a year earlier, with the FY2025 full-year figure at -$45.3 million, up 4.19% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$10.7 million, down from -$10.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for PALI reached as high as -$2.2 million in Q1 2025 and fell as low as -$10.7 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$3.5 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders surged 92.62% in 2022 and tumbled 382.02% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$3.9 million in 2022, then grew by 18.02% to -$3.2 million in 2023, then decreased by 7.29% to -$3.4 million in 2024, then plunged by 194.83% to -$10.0 million in 2025, then dropped by 7.64% to -$10.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.